Lev Gerlovin and Walter Colasante discuss the challenges posed to the biopharma business model by revolutionary, but prohibitively expensive, cell and gene therapies. To improve efficiencies and mitigate risk, drug developers now are looking at new options in stakeholder engagement and collaboration, as well as identifying new options for financing.
Read more here in The Pharma Letter Expert View: https://www.thepharmaletter.com/article/building-new-business-models-to-…
The authors wish to acknowledge the contributions of Pascale Diesel, Stephanie Donahue, and Michael Krepps to this article.
12 CRA consultants named top IP professionals in the 2021 IAM Patent 1000
12 CRA consultants were recognized as leading patent professionals by Intellectual Asset Management (IAM). The IAM Patent 1000 names the best-in-class patent...